Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$39.73M-5.1%-$37.8M-2.8%-$36.79M+12.6%-$42.08M+5.7%-$44.64M-19.1%
$351K-4.6%$368K-11.3%$415K-19.4%$515K+2.8%$501K-11.0%
$3.17M+17.4%$2.7M+0.1%$2.7M+7.2%$2.52M+16.5%$2.16M+56.4%
-$41.6M-24.1%-$33.53M+22.6%-$43.32M-35.6%-$31.95M+28.9%-$44.92M-21.2%
$2K-50.0%$4K$0-100%
-$50.2M$22.56M-22.7%$29.17M+423%$5.58M
$6.18M0.0%$6.18M0.0%$6.18M0.0%$6.18M
-$101K-100%$140.74M+9,359%$1.49M+329%-$649K-56.8%-$414K
-$91.9M-202%$89.93M+567%-$19.28M-462%-$3.43M+91.4%-$39.75M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kyverna Therapeutics, Inc. generate?
Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
What is Kyverna Therapeutics, Inc.'s free cash flow?
After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.